<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53109">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414789</url>
  </required_header>
  <id_info>
    <org_study_id>6084</org_study_id>
    <nct_id>NCT02414789</nct_id>
  </id_info>
  <brief_title>Lyme Borreliosis and Early Cutaneous Diagnostic</brief_title>
  <acronym>DIABOLYC</acronym>
  <official_title>Lyme Borreliosis and Early Cutaneous Diagnostic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test and evaluate a new diagnostic method (SRM-MS/MS: Selected Reaction Monitoring- Mass
      spectrometry) for Lyme Borreliosis on human skin biopsies. Patients included are those with
      the early skin manifestation (erythema migrans).

      This new proteomic method will be compared to the two existing method: culture of Borrelia
      and PCR detection of Borrelia (DNA detection of the bacteria).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the sensitivity (percentage of positive tests) of the SRM / MS-MS to techniques of PCR and culture Borrelia</measure>
    <time_frame>One year study</time_frame>
    <description>percentage of positive tests with all three techniques (SRM/MS-MS ; PCR ; culture)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>SRM / MS-MS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsies</intervention_name>
    <description>Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)</description>
    <arm_group_label>SRM / MS-MS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Erythema migrant as criteria EUCALB or atypical form associated to tick's sting

          -  Patient having signed a consent

          -  Patient affiliated to a social security scheme

        Exclusion Criteria:

          -  Prior treatment with antibiotics

          -  Erythema migrans on the face

          -  Bleeding disorders

          -  Anticoagulant treatment

          -  Inability to give clear information (subject in an emergency situation, understanding
             of the topic difficulty, ...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathalie BOULANGER, MD</last_name>
    <phone>+33369551449</phone>
    <email>nathalie.boulanger@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan LIPSKER, PhD</last_name>
    <phone>+33388116197</phone>
    <email>dan.lipsker@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier William Morey</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin MARTINOT, MD</last_name>
      <email>martin.martinot@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital E. Muller</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre KIEFFER, MD</last_name>
      <email>kiefferp@ch-mulhouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florent GRANGE, MD</last_name>
      <email>fgrange@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bel Air</name>
      <address>
        <city>Thionville</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François TRUCHETET, MD</last_name>
      <email>f.truchetet@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>August 6, 2015</lastchanged_date>
  <firstreceived_date>April 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erythema migrans</keyword>
  <keyword>Lyme</keyword>
  <keyword>early diagnosis</keyword>
  <keyword>skin biomarkers</keyword>
  <keyword>proteomics diagnostic</keyword>
  <keyword>mass spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
